Bisoprolol is selective for β₁ receptors, which reduces the likelihood of bronchospasm, but it can still affect β₂ receptors at higher doses. Patients with mild to moderate asthma should discuss the risk-benefit profile with their clinician and may require close monitoring.
Routine blood tests for liver and kidney function are sometimes ordered to monitor therapy, but bisoprolol itself does not typically interfere with standard laboratory measurements.
Most patients experience a reduction in systolic and diastolic pressure within 2-4 weeks of initiating therapy, though individual response times can vary.
Co-administration is common in hypertension management, but it may increase the risk of excessive blood-pressure reduction and slowed heart rate. Dose adjustments and regular monitoring are advisable.
Take the missed tablet as soon as you remember if it is more than 6 hours before your next scheduled dose; otherwise, skip it and resume your regular dosing schedule to avoid double dosing.
Alcohol can enhance the blood-pressure-lowering effect of bisoprolol and may increase dizziness. Moderate consumption is generally acceptable, but heavy drinking should be avoided.
In the UK, Zebeta 5 mg tablets are typically round, white, and imprinted with “5 ZB”, while 10 mg tablets are round, white, and imprinted with “10 ZB”. Appearance may vary with manufacturer batch.
Yes, generic bisoprolol tablets containing the same active ingredient and strength are considered therapeutically equivalent, provided they meet MHRA bio-equivalence standards.
Bisoprolol is not a prohibited substance under World Anti-Doping Agency (WADA) regulations, but athletes should disclose all prescribed medications to their sporting authority.
Tablets remain stable until the expiry date printed on the packaging, provided they are stored at room temperature, away from moisture and direct sunlight.
Zebeta is the brand name for bisoprolol, a beta-1 selective adrenergic blocker used to manage cardiovascular conditions. In the United Kingdom, bisoprolol is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as oral pills in strengths of 5 mg and 10 mg.
Bisoprolol binds selectively to beta-1 receptors located primarily in the heart. By blocking these receptors, it reduces the effects of adrenaline and noradrenaline, leading to:
Because beta-1 receptors are dominant in cardiac tissue, bisoprolol has minimal influence on beta-2 receptors in the lungs, making it relatively safer for patients with respiratory conditions. The drug is well absorbed after oral administration, with an onset of action within a few hours and a half-life of about 10-12 hours, supporting once-daily dosing.
Zebeta is approved by the MHRA for:
In clinical practice, it is also incorporated into guideline-directed therapy for chronic heart failure with reduced ejection fraction, although this specific indication is not listed on the product label in the UK.
Current peer-reviewed evidence supports the use of beta-1 blockers, including bisoprolol, for:
These uses are not approved by the MHRA for Zebeta. Off-label prescribing must be undertaken under close medical supervision and with individualized risk assessment.
Absolute contraindications
Relative contraindications
Special populations
If any of these occur, seek urgent medical attention.
This article provides educational information about Zebeta and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
